PRNewsWire · November 14, 2026
Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: PRNewsWire ↗